Rating Change
Roth Capital analysts initiated coverage on Avidity Biosciences, Inc. (NASDAQ:RNA) with a rating of Buy on October 22, 2026.
new coverageNASDAQ:RNA
Roth Capital Initiates Coverage on Avidity Biosciences, Inc. (RNA) with Buy
Roth Capital analysts initiated coverage on Avidity Biosciences, Inc. (NASDAQ:RNA) with a rating of Buy on October 22, 2026.
At publication ·
What changed
Avidity Biosciences, Inc. (NASDAQ:RNA) · new coverage
- Firm
- Roth Capital
- Rating
- Buy
- Price at event
- $8.13
- Market capitalization
- $9.4B
At a glance
Key takeaways
- Roth Capital initiated Buy coverage on Avidity Biosciences (RNA) on October 22, 2026, with the stock trading at $8.13 and a market cap of $9.4 billion.
Market Context
Avidity Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $8.13 with a market capitalization of $9.4B. The stock has declined 83.7% over the past 52 weeks.
Analyst coverage from Roth Capital provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Avidity Biosciences, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Avidity Biosciences, Inc.
Among the 10 most recent ratings: 6 Buy, 4 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 22, 2026 | Roth Capital | Buy | N/A |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 06, 2026 | HC Wainwright & Co. | Buy | N/A |
| Jun 18, 2026 | Cantor Fitzgerald | Overweight | N/A |
| May 15, 2026 | Leerink Partners | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View RNA Stock Page
Frequently Asked Questions
What does the Buy rating mean for RNA?
A rating of Buy from Roth Capital reflects the analyst's outlook on Avidity Biosciences, Inc. (NASDAQ:RNA). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RNA forecast page.